Wednesday, July 09, 2025 10:29:52 AM
A quick comment on Mill Creek:
First off, this technology by Mill Creek is a little misleading because they’re not comparing their technology to DCVax technology; they claim other Dendritic Cell vaccines take “several months” to develop the “autologous tumor lysate”. That’s because others are expanding tumor cell lines in vitro from tumor samples instead of using the “freeze/thaw” method DCVax uses and has as part of their patent portfolio. These guys are trying to get around DCVax’s patents by using their technique to expand tumor antigens in the lab that creates a “library” of tumor antigens and then they do a genetic sampling of each patient’s tumor and match it with their “library” of antigens to choose which ones to use for their vaccine. It’s basically a work around. What they’re also missing is how the DCs themselves are manufactured and likely have nothing close to what NWBO has or the ability to mass manufacture DCs let alone to the high quality making. I’m guessing they’ll want to eventually come to NWBO as a partner in some way for at least the DCs
And by the way; NWBO can make the tumor lysate in 4-7 days once the tumor gets to Advent, not “several months”!!!!
AND, major biotechs have been trying to work around NWBO's patents for years and have been unable to do it !!! If MRK and the other big boys can't beat Linda Powers at the "Patent Game", why would anyone ever believe that little Mill Creek could :):):) !!! The "Bad Guys" are pulling out all the stops in their last desperate attempt to derail NWBO and their DCVax-L, breakthrough, platform technology for treating all large tumor cancers, cancers of all types, bacterias, diseases and viruses. NWBO's breakthrough technology is "PEERLESS" !!!!
Cheers,
BB
First off, this technology by Mill Creek is a little misleading because they’re not comparing their technology to DCVax technology; they claim other Dendritic Cell vaccines take “several months” to develop the “autologous tumor lysate”. That’s because others are expanding tumor cell lines in vitro from tumor samples instead of using the “freeze/thaw” method DCVax uses and has as part of their patent portfolio. These guys are trying to get around DCVax’s patents by using their technique to expand tumor antigens in the lab that creates a “library” of tumor antigens and then they do a genetic sampling of each patient’s tumor and match it with their “library” of antigens to choose which ones to use for their vaccine. It’s basically a work around. What they’re also missing is how the DCs themselves are manufactured and likely have nothing close to what NWBO has or the ability to mass manufacture DCs let alone to the high quality making. I’m guessing they’ll want to eventually come to NWBO as a partner in some way for at least the DCs
And by the way; NWBO can make the tumor lysate in 4-7 days once the tumor gets to Advent, not “several months”!!!!
AND, major biotechs have been trying to work around NWBO's patents for years and have been unable to do it !!! If MRK and the other big boys can't beat Linda Powers at the "Patent Game", why would anyone ever believe that little Mill Creek could :):):) !!! The "Bad Guys" are pulling out all the stops in their last desperate attempt to derail NWBO and their DCVax-L, breakthrough, platform technology for treating all large tumor cancers, cancers of all types, bacterias, diseases and viruses. NWBO's breakthrough technology is "PEERLESS" !!!!
Cheers,
BB
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
